



Financial Tear Sheet

Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.



Recent News & Investor Events

05/22/17

Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry

05/04/17

Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results

04/27/17

Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome

There are currently no events scheduled.

SEC Filings

Filing Date	Form	Description
05/23/17	4	Statement of changes in beneficial ownership of securities
05/23/17	4	Statement of changes in beneficial ownership of securities
05/23/17	4	Statement of changes in beneficial ownership of securities
05/23/17	4	Statement of changes in beneficial ownership of securities